tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2020 Jul 2;1-5.
doi: 10.1080/21645515.2020.1754052. Online ahead of print.
Suboptimal Uptake of Meningococcal Vaccines Among Older Adolescents: Barriers, Solutions, and Future Research Directions
Linda M Niccolai[SUP] 1 [/SUP], Caitlin E Hansen[SUP] 2 [/SUP]
Affiliations
Abstract
Over the past 15 y, several vaccines have been added to the recommended immunization schedule for adolescents in the United States. In addition to annual influenza vaccination, the Advisory Committee on Immunization Practices recommends tetanus, diphtheria, and pertussis (Tdap), meningococcal conjugate (MenACWY), and human papillomavirus (HPV) vaccine for routine administration at ages 11-12 y, and a second dose of MenACWY at age 16. A vaccine against meningococcal disease caused by serogroup B (MenB) is also available and recommended for shared clinical decision-making. Though notable gains in uptake have been achieved for some adolescent vaccines, coverage varies considerably with lower rates for HPV vaccine and second dose of MenACWY. Coverage for MenB is especially low. While extensive research has focused on barriers to and solutions for higher uptake of HPV vaccine, limited attention has been given to the reasons for lower uptake of meningococcal vaccines among older adolescents. This purpose of this commentary is to discuss barriers to and solutions for higher uptake of meningococcal vaccines among older adolescents, and to identify gaps in knowledge that can inform research efforts going forward.
Keywords: Adolescents; coverage; meningococcal; vaccination; vaccine.
. 2020 Jul 2;1-5.
doi: 10.1080/21645515.2020.1754052. Online ahead of print.
Suboptimal Uptake of Meningococcal Vaccines Among Older Adolescents: Barriers, Solutions, and Future Research Directions
Linda M Niccolai[SUP] 1 [/SUP], Caitlin E Hansen[SUP] 2 [/SUP]
Affiliations
- PMID: 32614695
- DOI: 10.1080/21645515.2020.1754052
Abstract
Over the past 15 y, several vaccines have been added to the recommended immunization schedule for adolescents in the United States. In addition to annual influenza vaccination, the Advisory Committee on Immunization Practices recommends tetanus, diphtheria, and pertussis (Tdap), meningococcal conjugate (MenACWY), and human papillomavirus (HPV) vaccine for routine administration at ages 11-12 y, and a second dose of MenACWY at age 16. A vaccine against meningococcal disease caused by serogroup B (MenB) is also available and recommended for shared clinical decision-making. Though notable gains in uptake have been achieved for some adolescent vaccines, coverage varies considerably with lower rates for HPV vaccine and second dose of MenACWY. Coverage for MenB is especially low. While extensive research has focused on barriers to and solutions for higher uptake of HPV vaccine, limited attention has been given to the reasons for lower uptake of meningococcal vaccines among older adolescents. This purpose of this commentary is to discuss barriers to and solutions for higher uptake of meningococcal vaccines among older adolescents, and to identify gaps in knowledge that can inform research efforts going forward.
Keywords: Adolescents; coverage; meningococcal; vaccination; vaccine.